Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdvaMed President Ubl Sets Ambitious FDA Performance, International Goals

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed President Steve Ubl aims to have FDA meeting a 180-day review deadline for expedited PMAs in the next three to five years and to revamp Japan's reimbursement system in the next two years

You may also be interested in...



AdvaMed Hires Former Bush Aide As Top Lobbyist

A former aide to President Bush on health legislation will join AdvaMed Jan. 16 to head up the group's lobbying efforts

AdvaMed Hires Former Bush Aide As Top Lobbyist

A former aide to President Bush on health legislation will join AdvaMed Jan. 16 to head up the group's lobbying efforts

Industry Favors Predictability Over Speed In Next Round Of MDUFMA

Senior device industry staffers are more interested in improving the predictability of FDA's premarket review process than pushing the agency to accelerate its performance, an FDA 1report suggests

Related Content

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel